OUR
PIPELINE
Combi-X: FIXED DOSE
COMBINATION (FDC)
PRODUCT FOR MIGRAINE
PROPHYLAXIS
COMBINATION (FDC)
PRODUCT FOR MIGRAINE
PROPHYLAXIS
DEVELOPMENT OF A FIXED-COMBINATION DRUG FOR MIGRAINE PROPHYLAXIS
Migraine, a debilitating disease affecting 17% of women and 6% of men, dramatically decreases
quality of life and can cause severe temporary incapacity for work. Approximately 38% of
migraine patients, having more than 2 attacks a month, would require prophylactic treatment, but
current medications have serious issues. Our new fixed-dose combination utilizes drugs with good
safety and tolerability profiles and expected to provide better and more cost-effective
prophylactic treatment for migraineurs than currently available medications (e.g., topiramate,
beta-blockers, CGRP inhibitors). Due to the different mechanism of action, it may also target
cases being resistant to current therapies.
The supraadditive interaction of the constituents and thus the high in vivo efficacy of the combination have been proven in a human-relevant in vivo rat model of migraine.
CTXA: MMP2 INHIBITOR
FOR CANCER DIAGNOSIS
AND TREATMENT
FOR CANCER DIAGNOSIS
AND TREATMENT
NEW ANTITUMOR MEDICATION FROM SCORPION VENOM TARGETING MATRIX METALLOPROTEINASE-2 (MMP-2)
In this project we develop new molecules for the therapy and diagnostics of MMP-2-expressing
tumors, such as glioblastoma (GBM). Based on chlorotoxin (CTX), a natural miniprotein under
clinical development, we developed a lead compound showing superiority in terms both affinity
and selectivity compared to CTX. We filed a patent application covering a wide range of
miniproteins (PCT/HU2021/050075). All claims of this application have been accepted in terms of
all requirements of patentability in its International Preliminary Report on Patentability.
Our lead compound, applied as a targeting molecule in chimeric antigen receptor (CAR) T-cell therapy, has been shown to have strong effect in an in vivo glioblastoma (GBM) mouse model.
Kv1.3: SELECTIVE POTASSIUM
CHANNEL INHIBITOR
FOR AUTOIMMUNE
DISEASES
CHANNEL INHIBITOR
FOR AUTOIMMUNE
DISEASES
NEW TREATMENT FOR AUTOIMMUNE DISEASES EMPLOYING AN IMMUNE-SPARING MECHANISM OF ACTION
Autoimmune diseases place a heavy burden on society and all current medications are based on
general immunosuppression. Sustained activation of effector memory T cells (TEM) plays a key
role in the pathomechanism of autoimmune diseases. A unique property of these cells that they
excessively rely on Kv1.3 potassium channels for persistent activation. Therefore, selective
inhibition of Kv1.3 is a promising tool to treat autoimmune diseases safely and effectively
without general immunosuppression.
Our lead compound has been shown to have strong in vivo effect in a rat delayed-type hypersensitivity model.
CREATE:
NEW CLASS OF CNS MEDICATION EMPLOYING SMALL MOLECULE-CONTROLLED GENE THERAPY
NEW CLASS OF CNS MEDICATION EMPLOYING SMALL MOLECULE-CONTROLLED GENE THERAPY
DEVELOPMENT OF A MODIFIED RECEPTOR THAT ALLOWS PHARMACEUTICAL TARGETING OF SPECIFIC NEURONAL
POPULATIONS
Chemogenetic receptors are exclusively activated by their pharmaceutical ligand (actuator).
CNS-delivered chemogenetic receptors have no physiological effects without their actuator,
offering a flexible and adaptive control of the timing and intensity of the effect. Providing a
safe, adjustable alternative, the aim of this project is to replace some of the current
neurosurgery techniques, such as deep brain stimulation and local lesion. Moreover, molecular
targeting solutions (e.g. promoters) allow distinction between neuronal populations not only
based on their localization, but also based on their neurochemical attributes. On the long run,
non-surgical delivery may provide additional benefits to this platform.
↑
